Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended April 5, 2026.

Several leading In Vitro Diagnostic (IVD) companies have posted their first-quarter results for 2026, showing mixed performance across revenue, profitability, and cash flow.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 28, 2026.

Group sales were +6% at constant exchange rates (CER), -5% when reported in CHF and +9% in USD, in the first three months, driven by high demand for our innovative medicines and diagnostics.

Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2026.

Danaher Corporation (NYSE: DHR) today announced results for the first quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.

QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, today announced preliminary unaudited revenue for the first quarter of 2026, ended March 29, 2026, and provided an update on its full-year 2026 financial guidance. The Company also announced its plan to release its full first quarter 2026 financial results on Tuesday, May 5, 2026, after the market closes.

Our cancer diagnostics business, medical devices portfolio and pipeline progress are among key growth drivers.

Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.86 billion for the fourth quarter ended October 31, 2025, exceeding revenue guidance and representing growth of 9.4% reported and up 7.2% core(1) compared with the fourth quarter of 2024.

MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a leading precision diagnostics company, today announced its financial results for the three and nine-month period ended September 30, 2025.